Cargando…

P1442: PRACTICE-BASED EVIDENCE: LONG-TERM SAFETY COHORT OF DEFERIPRONE IN PATIENTS WITH SICKLE CELL DISEASE FROM THE US REGISTRY

Detalles Bibliográficos
Autores principales:	Badawy, Sherif, Thompson, Alexis, Tricta, Fernando, Toiber Temin, Noemi, Fradette, Caroline, Rozova, Anna, Kwiatkowski, Janet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430531/ http://dx.doi.org/10.1097/01.HS9.0000972652.29437.94

Ejemplares similares

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
por: Elalfy, Mohsen S., et al.
Publicado: (2022)

The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease
por: Soulières, Denis, et al.
Publicado: (2022)

S115: LONG-TERM EFFICACY AND SAFETY OF DEFERIPRONE FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

P1558: EARLY-START DEFERIPRONE IN INFANTS/YOUNG CHILDREN WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA: EVIDENCE FOR IRON SHUTTLING TO TRANSFERRIN—RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (START)
por: Tricta, F., et al.
Publicado: (2022)

S123: SAFETY AND EFFICACY OF EARLY-START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA-THALASSEMIA (START STUDY)
por: Elalfy, M, et al.
Publicado: (2022)

S120: RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON-OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

5613341 REAL-WORLD CHANGES IN KIDNEY FUNCTION FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANAEMIAS RECEIVING IRON CHELATION THERAPY IN THE US
por: Sunil Bhandari, S.B., et al.
Publicado: (2023)

The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study
por: Badawy, Sherif M., et al.
Publicado: (2021)

Deferiprone‐induced agranulocytosis: 20 years of clinical observations
por: Tricta, Fernando, et al.
Publicado: (2016)

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone
por: Fradette, Caroline, et al.
Publicado: (2016)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW
por: Kattamis, A., et al.
Publicado: (2022)

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
por: Kwiatkowski, Janet L., et al.
Publicado: (2022)

Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Sphenoid Sinus Diseases: A Review of 1,442 Patients
por: Fooanant, Supranee, et al.
Publicado: (2017)

Association between Participants' Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease
por: Badawy, Sherif M., et al.
Publicado: (2018)

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease
por: Martin-Bastida, Antonio, et al.
Publicado: (2017)

Salmonella Typhimurium and Pseudomonas aeruginosa Respond Differently to the Fe Chelator Deferiprone and to Some Novel Deferiprone Derivatives
por: Ammendola, Serena, et al.
Publicado: (2021)

Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review
por: Holubarsch, Christian J. F., et al.
Publicado: (2017)

Epidemiology and outcome of 1442 pediatric burn patients: A single-center experience
por: Özlü, Özer, et al.
Publicado: (2022)

Fetal hemoglobin level and nutritional status in patients with sickle cell disease
por: Badawy, Sherif M.
Publicado: (2016)

Nanomechanics and Sodium Permeability of Endothelial Surface Layer Modulated by Hawthorn Extract WS 1442
por: Peters, Wladimir, et al.
Publicado: (2012)

1442. Use of a Spaced-Education Platform to Assess Hand Hygiene Auditor Competency
por: Vaughan-Malloy, Ana M, et al.
Publicado: (2023)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease
por: Barriteau, Christina M, et al.
Publicado: (2022)

Safety and Efficacy of Topical Chitogel- Deferiprone-Gallium Protoporphyrin in Sheep Model
por: Ooi, Mian L., et al.
Publicado: (2018)

Patient-Centered eHealth Interventions for Children, Adolescents, and Adults With Sickle Cell Disease: Systematic Review
por: Badawy, Sherif M, et al.
Publicado: (2018)

Correction: Nanomechanics and Sodium Permeability of Endothelial Surface Layer Modulated by Hawthorn Extract WS 1442
por: Peters, Wladimir, et al.
Publicado: (2013)

1442. Acquisition and Transferability Mechanisms of Mercury Resistance Genes in Latin-American Staphylococcus aureus Strains
por: Ortega-Recalde, Oscar, et al.
Publicado: (2020)

Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone
por: Porter, John B, et al.
Publicado: (2013)

Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment
por: Goncalves, Sergio, et al.
Publicado: (2008)

Quantum chemical analysis of the deferiprone–iron binding reaction
por: Wiwanitkit, Viroj
Publicado: (2006)

Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci
por: Kim, Choon-Mee, et al.
Publicado: (2009)

Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients
por: Won, Sung Chul, et al.
Publicado: (2010)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
por: Pepe, Alessia, et al.
Publicado: (2013)

Symptomatic treatment of premenstrual syndrome and/or primary dysmenorrhea with DLBS1442, a bioactive extract of Phaleria macrocarpa
por: Tjandrawinata, Raymond R, et al.
Publicado: (2011)

Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults
por: Badawy, Sherif M., et al.
Publicado: (2017)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gaummr2ns6jf6rr0hktrgfkbd3